E.B. Brakewood
Immuneering Corp Executive Business Consultant
Cambridge, Mass
I joined immuneering in 2023 as an executive business consultant. Previously I was VP and head of a business unit at Regeneron responsible for oncology, covid19, and new product planning, and prior to that I was with Merck (MSD) in various commercial roles of increasing responsibility.
Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients. Our initial aim is to develop a universal-RAS therapy, an approach designed to include patients with solid tumors driven by any mutation in KRAS, NRAS, or HRAS. Our inclusive approach differentiates us from narrowly targeted precision therapies, which are limited to patients with tumors harboring select mutations.
We hosted our very first earnings call March 6. An archive of that event plus recently updated Corporate Presentation and 10k statement are available on our website.